All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub was pleased to speak to Theo de Witte, Radboud University Medical Center, Nijmegen, NL. We asked, Is there confusion between the World Health Organisation (WHO) and Molecular International Prognostic Scoring System (IPSS-M) classifications of myelodysplastic syndromes (MDS)?
Is there confusion between WHO and IPSS-M classifications of MDS?
De Witte begins by discussing the basis of the current IPSS-M criteria on cytogenetics characteristics, blast percentage, and severity of cytopenia, despite half of patients diagnosed with MDS having normal karyotypes. Moving on, De Witte compares the IPSS-M with the recently updated WHO classification and its focus on diagnosis and morphological features. De Witte emphasizes the importance of identifying specific genetic mutations to determine prognosis more accurately, omitted from the WHO classification.
How do we differentiate high-risk MDS from AML?
During the EHA 2022 Congress, the MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, How do we differentiate high-risk MDS from AML?
What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?
The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Rena Buckstein, and featured Theo de Witte, Silvia...
New IPSS-Molecular model for MDS risk stratification and prognosis
Bernard, et al. evaluated the combined prognostic power of hematologic, cytogenetic, and somatic gene mutation parameters in the development and use of a clinical-molecular...
Subscribe to get the best content related to MDS delivered to your inbox